The impact of glucocorticoid polymorphisms on markers of neonatal respiratory disease after antenatal betamethasone administration

American Journal of Obstetrics and Gynecology

Volumn 208, Issue 3, 2013, Pages 215.e1-215.e6

  Haas, David M ^a   Dantzer, Jessica ^a   Lehmann, Amalia S ^a   Philips, Santosh ^a   Skaar, Todd C ^a   McCormick, Catherine L ^a   Hebbring, Scott J ^b   Jung, Jeesun ^a   Li, Lang ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

antenatal corticosteroid; betamethasone; pharmacogenetics

Indexed keywords

ARTIFICIAL LUNG SURFACTANT; BETAMETHASONE;

ADULT; ARTICLE; ASSISTED VENTILATION; BRAIN HEMORRHAGE; CHILDBIRTH; CHORIOAMNIONITIS; DELIVERY; DISEASE SEVERITY; DRUG METABOLISM; FEMALE; GENE; GENOTYPE; GESTATIONAL AGE; HUMAN; HUMAN TISSUE; IMPORTIN 13 GENE; INFANT; LOGISTIC REGRESSION ANALYSIS; LUNG DYSPLASIA; MAJOR CLINICAL STUDY; MALE; NECROTIZING ENTEROCOLITIS; NEONATAL RESPIRATORY DISTRESS SYNDROME; NEWBORN; NEWBORN DEATH; NEWBORN SEPSIS; PRENATAL PERIOD; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84874760547     PISSN: 00029378     EISSN: 10976868     Source Type: Journal    
DOI: 10.1016/j.ajog.2012.12.031     Document Type: Article

References (25)

1. American College of Obstetricians and Gynecologists Management of preterm labor: ACOG practice bulletin no. 43 Obstet Gynecol 101 2003 1039 1047
2. W.P. Frisbie, D. Forbes, S.G. Pullum Compromised birth outcomes and infant mortality among racial and ethnic groups Demography 33 1996 469 481
3. W.P. Frisbie, S.E. Song, D.A. Powers, J.A. Street The increasing racial disparity in infant mortality: respiratory distress syndrome and other causes Demography 41 2004 773 800
4. V. Kavvadia, A. Greenough, G. Dimitriou, R. Hooper Influence of ethnic origin on respiratory distress syndrome in very premature infants Arch Dis Child Fetal Neonatal Ed 78 1998 F25 F28
5. M.H. Ensom, T.K. Chang, P. Patel Pharmacogenetics: the therapeutic drug monitoring of the future? Clin Pharmacokinet 40 2001 783 802
6. S.A. Scott, K. Sangkuhl, E.E. Gardner Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy Clin Pharmacol Ther 90 2011 328 332
7. D. Grossniklaus Testing of VKORC1 and CYP2C9 alleles to guide warfarin dosing: test category: pharmacogenomic (treatment) PLoS Curr 2 2010
8. S. Crettol, J.P. Venetz, M. Fontana, J.D. Aubert, M. Pascual, C.B. Eap CYP3A7, CYP3A5, CYP3A4, and ABCB1 genetic polymorphisms, cyclosporine concentration, and dose requirement in transplant recipients Ther Drug Monit 30 2008 689 699
9. D.M. Haas, A.S. Lehmann, T. Skaar The impact of drug metabolizing enzyme polymorphisms on outcomes after antenatal corticosteroid use Am J Obstet Gynecol 206 2012 447.e17 447.e24
10. B.J. Stoll, N.I. Hansen, E.F. Bell Neonatal outcomes of extremely preterm infants from the NICHD Neonatal Research Network Pediatrics 126 2010 443 456
11. G.A. Hawkins, R. Lazarus, R.S. Smith The glucocorticoid receptor heterocomplex gene STIP1 is associated with improved lung function in asthmatic subjects treated with inhaled corticosteroids J Allergy Clin Immunol 123 2009 1376 1383.e7
12. B.A. Raby, K. Van Steen, J. Lasky-Su Importin-13 genetic variation is associated with improved airway responsiveness in childhood asthma Respir Res 10 2009 67
13. K. Tantisira, S. Weiss, K. Tantisira, S. Weiss The pharmacogenetics of asthma treatment Curr Allergy Asthma Rep 9 2009 10 17
14. K.G. Tantisira, S. Lake, E.S. Silverman Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids Hum Mol Genet 13 2004 1353 1359
15. S.T. Weiss, S.L. Lake, E.S. Silverman Asthma steroid pharmacogenetics: a study strategy to identify replicated treatment responses Proc Am Thorac Soc 1 2004 364 367
16. J.K. Lamba, Y.S. Lin, E.G. Schuetz, K.E. Thummel Genetic contribution to variable human CYP3A-mediated metabolism Adv Drug Deliv Rev 54 2002 1271 1294
17. S. Cholerton, A.K. Daly, J.R. Idle The role of individual human cytochromes P450 in drug metabolism and clinical response Trends Pharmacol Sci 13 1992 434 439
18. T.S. Tracy, R. Venkataramanan, D.D. Glover, S.N. Caritis Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy Am J Obstet Gynecol 192 2005 633 639
19. P. Smit, R.H. van Schaik, M. van der Werf A common polymorphism in the CYP3A7 gene is associated with a nearly 50% reduction in serum dehydroepiandrosterone sulfate levels J Clin Endocrinol Metab 90 2005 5313 5316
20. E.S. Koster, A.H. Maitland-van der Zee, R. Tavendale FCER2 T2206C variant associated with chronic symptoms and exacerbations in steroid-treated asthmatic children Allergy 66 2011 1546 1552
21. K.G. Tantisira, E.S. Silverman, T.J. Mariani FCER2: a pharmacogenetic basis for severe exacerbations in children with asthma J Allergy Clin Immunol 120 2007 1285 1291
22. X.W. Hou, L.F. Wang, N. Wang The G501C polymorphism of oxidized LDL receptor gene [OLR-1] is associated with susceptibility and serum C-reactive protein concentration in Chinese essential hypertensives Clin Chim Acta 388 2008 200 203
23. M.F. Hebert, T.R. Easterling, B. Kirby Effects of pregnancy on CYP3A and P-glycoprotein activities as measured by disposition of midazolam and digoxin: a University of Washington specialized center of research study Clin Pharmacol Ther 84 2008 248 253
24. P.L. Ballard, P. Granberg, R.A. Ballard Glucocorticoid levels in maternal and cord serum after prenatal betamethasone therapy to prevent respiratory distress syndrome J Clin Invest 56 1975 1548 1554
25. M.F. Hebert, X. Ma, S.B. Naraharisetti Are we optimizing gestational diabetes treatment with glyburide? The pharmacologic basis for better clinical practice Clin Pharmacol Ther 85 2009 607 614